Multidrug-resistant tuberculosis (MDR-TB)
A course of treatment for uncomplicated tuberculosis (TB) takes a minimum of six months. When patients are resistant to the two most powerful first-line antibiotics (isoniazid and rifampicin), they are considered to have multidrug-resistant TB (MDR-TB).
MDR-TB is not impossible to treat, but the drug regimen is arduous, taking up to two years and causing many side effects.
Extensively drug-resistant tuberculosis (XDR-TB) is identified when patients show resistance to the second-line drugs administered for MDR-TB. The treatment options for XDR-TB are very limited. Two new drugs – bedaquiline and delamanid – have recently become available to some patients who have no other treatment options left.
In 2015 MSF treated 18,100 patients for TB, of whom 2,000 for MDR-TB.
For more information, please see tuberculosis.
- Access to essential medicineApply Access to essential medicine filter (38)
- Access to healthcareApply Access to healthcare filter (9)
- Antibiotic resistanceApply Antibiotic resistance filter (3)
- Child healthApply Child health filter (2)
- Health policyApply Health policy filter (3)
- Maternal healthApply Maternal health filter (2)
- Mental healthApply Mental health filter (6)
- MigrantApply Migrant filter (2)
- Mobile clinicApply Mobile clinic filter (2)
- Neglected diseasesApply Neglected diseases filter (3)
- Refugees and IDPsApply Refugees and IDPs filter (2)
- Extensively drug-resistant tuberculosis (XDR-TB)Apply Extensively drug-resistant tuberculosis (XDR-TB) filter (34)
- Hepatitis CApply Hepatitis C filter (1)
- HIV / AIDSApply HIV / AIDS filter (10)
- Infectious diseasesApply Infectious diseases filter (14)
- MalariaApply Malaria filter (1)
- MalnutritionApply Malnutrition filter (1)
- MeaslesApply Measles filter (1)
- Multidrug-resistant tuberculosis (MDR-TB)Apply Multidrug-resistant tuberculosis (MDR-TB) filter (103)
- Parasitic diseasesApply Parasitic diseases filter (1)
- TuberculosisApply Tuberculosis filter (103)